What question did this study set out to answer?

To evaluate the diagnostic and prognostic utility of FDG-PET/CT in patients with extracardiac sarcoidosis who present with no high-risk cardiac features and normal CMR findings.

March 2, 2025European Heart Journal - Cardiovascular ImagingOpen Access

The role of FDG-PET/CT in assessing cardiac sarcoidosis with no high-risk cardiac features and normal CMR

View Full Paper

Ask AI

Bookmark

Why the study?

Diagnosing cardiac sarcoidosis is challenging due to variable presentation and lack of consensus on screening, prompting evaluation of FDG-PET/CT in patients with normal CMR and no high-risk cardiac features.

Does FDG-PET/CT provide diagnostic and prognostic value in patients with extracardiac sarcoidosis, no high-risk cardiac features, and normal CMR?

Key Points

To evaluate the diagnostic and prognostic utility of FDG-PET/CT in patients with extracardiac sarcoidosis who present with no high-risk cardiac features and normal CMR findings.
Retrospective, single-centre cohort study including biopsy-confirmed extracardiac sarcoidosis patients (N=324) without high-risk cardiac features who had normal CMR and underwent FDG-PET/CT.
Evaluated multidisciplinary team diagnostic categorization (unlikely, possible, probable cardiac sarcoidosis) and tracked adverse cardiac events over a median follow-up of 38.1 months.
Cardiac FDG uptake occurred in 69 of 324 patients (21.3%), but 55.2% with suggestive uptake were ultimately classified as unlikely cardiac sarcoidosis, leaving 305 (94.1%) unlikely, 17 (5.3%) possible, and 2 (0.6%) probable.
Adverse cardiac events occurred in 15 patients (3.4%; annualized 1.1%), affecting only 5 of 69 patients (7.2%) with cardiac FDG uptake, with all 5 cardiac deaths occurring in the unlikely cardiac sarcoidosis cohort.

Structured PICO

Does FDG-PET/CT provide diagnostic and prognostic value in patients with extracardiac sarcoidosis, no high-risk cardiac features, and normal CMR?

Population

324 patients with biopsy-confirmed extracardiac sarcoidosis who underwent CMR and FDG-PET/CT, with no high-risk cardiac features and normal CMR

Intervention

18F-fluorodeoxyglucose positron emission tomography with computed tomography (FDG-PET/CT)

Outcome

Diagnostic value of FDG-PET/CT in the assessment for cardiac sarcoidosis by a multi-disciplinary team (MDT)surrogate

FDG-PET/CT offers limited diagnostic and prognostic value in patients with extracardiac sarcoidosis who have no high-risk cardiac features and normal CMR, a population that inherently has a low risk of adverse cardiac events.

Authors

FSF ShuduyevaSt. Antonius Ziekenhuis ABAnnelies L.M. BakkerSt. Antonius Ziekenhuis FAFatima AkdimSt. Antonius Ziekenhuis

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

FDG-PET/CT adds limited value in low-risk sarcoidosis with normal CMR; leaves open its role in broader screening pending prospective data.

Cite This Study

Shuduyeva et al. (2025) studied this question.

synapsesocial.com/papers/6a86552bd94e0117716392c8 https://doi.org/10.1093/ehjci/jeaf074

Topics

Cardiac MRI Cardiomyopathy Cardiac amyloidosis

View Full Paper

Ask AI

Bookmark

Implication

FDG-PET/CT adds limited value in low-risk sarcoidosis with normal CMR; leaves open its role in broader screening pending prospective data.

The role of FDG-PET/CT in assessing cardiac sarcoidosis with no high-risk cardiac features and normal CMR

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Topics

The role of FDG-PET/CT in assessing cardiac sarcoidosis with no high-risk cardiac features and normal CMR

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider